Share Price and Basic Stock Data
Last Updated: October 22, 2025, 8:57 am
| PEG Ratio | 251.12 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Gujarat Themis Biosyn Ltd operates in the pharmaceuticals sector, recording a sales figure of ₹148 Cr for the fiscal year ending March 2023, a notable increase from ₹115 Cr in the previous year. The company has shown a consistent upward trajectory in sales, with figures reaching ₹170 Cr for March 2024 and slightly declining to ₹151 Cr for March 2025, reflecting a robust growth pattern overall. Quarterly sales also demonstrate volatility, peaking at ₹49.59 Cr in June 2023 before falling to ₹39.54 Cr in September 2023. The operating profit margin (OPM) stood at 38.81% as of the latest reporting, indicating strong operational efficiency, although there was a decline from the higher margins recorded previously. The company’s ability to generate revenue from operations remains strong, supported by its strategic positioning in the pharmaceutical market, which is characterized by significant growth potential and increasing demand for healthcare solutions.
Profitability and Efficiency Metrics
The profitability metrics of Gujarat Themis Biosyn Ltd reflect a solid financial performance amidst fluctuating revenue. The net profit for the year ending March 2025 was reported at ₹49 Cr, a decrease from ₹58 Cr in March 2023, yet the company maintains a healthy return on equity (ROE) of 21.7% and a return on capital employed (ROCE) of 27.3%. The interest coverage ratio (ICR) is notably high at 195.82x, indicating that the company can comfortably meet its interest obligations. However, the cash conversion cycle (CCC) has been reported at -67 days, suggesting efficient management of working capital, yet also raising concerns about potential liquidity issues if the operational dynamics shift. The decline in operating profit margin to 38.81% highlights pressure on profitability, which warrants attention to cost management and revenue enhancement strategies moving forward.
Balance Sheet Strength and Financial Ratios
Gujarat Themis Biosyn Ltd’s balance sheet exhibits a strong capital structure with total borrowings of ₹30 Cr against reserves of ₹237 Cr, resulting in a low debt-to-equity ratio of 0.12. This indicates a conservative approach to leverage, enhancing financial stability. The company’s liquidity ratios are robust, with a current ratio of 2.53 and a quick ratio of 2.28, signifying that it can cover short-term liabilities comfortably. The book value per share stands at ₹22.79, which is relatively low compared to its market price of ₹422, resulting in a high price-to-book value (P/BV) ratio of 12.35x. This valuation may suggest that the market has high expectations for future growth. Furthermore, the return on assets (ROA) of 16.18% is commendable, reflecting effective utilization of assets in generating profits. Overall, the balance sheet appears solid, though the high P/BV ratio may warrant scrutiny regarding market expectations.
Shareholding Pattern and Investor Confidence
The shareholding structure of Gujarat Themis Biosyn Ltd reveals a strong promoter backing, with promoters holding 70.87% of the share capital. This substantial stake indicates confidence from the founding members in the company’s direction and governance. Foreign institutional investors (FIIs) have gradually increased their stake to 2.51%, while domestic institutional investors (DIIs) hold a modest 1.17%. The public shareholding stands at 25.44%, with a notable increase in the number of shareholders, which reached 28,945 by June 2025, up from 17,373 in June 2023. This rising trend in shareholder numbers reflects growing interest and confidence in the company. However, the low percentage of institutional ownership may pose a risk regarding the stock’s volatility and liquidity. Overall, the shareholding pattern indicates strong promoter confidence, which could positively influence investor sentiment.
Outlook, Risks, and Final Insight
If the company can sustain its current operating profit margins and effectively manage its cost structure, it may continue to benefit from the growing pharmaceutical market. However, risks remain, particularly concerning the volatility in quarterly sales and the decline in net profit figures. Additionally, the high P/BV ratio suggests that the market has elevated expectations, which may be challenging to meet without consistent revenue growth. The company’s ability to navigate potential liquidity issues, evidenced by its cash conversion cycle, will be crucial in maintaining operational efficiency. If Gujarat Themis Biosyn Ltd can enhance its revenue streams and maintain strong promoter backing, it may solidify its position in the market, driving long-term value for shareholders. Nonetheless, vigilance regarding market conditions and internal efficiencies will be essential for sustaining investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Gujarat Themis Biosyn Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,993 Cr. | 458 | 465/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 38.1 Cr. | 51.3 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.9 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,038.24 Cr | 1,197.65 | 50.64 | 194.07 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 44.94 | 47.69 | 28.17 | 27.59 | 49.59 | 39.54 | 38.78 | 42.01 | 38.83 | 34.72 | 39.52 | 37.74 | 35.87 |
| Expenses | 22.16 | 23.29 | 16.06 | 13.23 | 26.07 | 22.82 | 21.11 | 21.09 | 20.27 | 19.33 | 20.66 | 21.70 | 21.95 |
| Operating Profit | 22.78 | 24.40 | 12.11 | 14.36 | 23.52 | 16.72 | 17.67 | 20.92 | 18.56 | 15.39 | 18.86 | 16.04 | 13.92 |
| OPM % | 50.69% | 51.16% | 42.99% | 52.05% | 47.43% | 42.29% | 45.56% | 49.80% | 47.80% | 44.33% | 47.72% | 42.50% | 38.81% |
| Other Income | 1.42 | 1.40 | 1.81 | 1.96 | 1.07 | 1.10 | 1.08 | 1.02 | 0.52 | 0.32 | 0.24 | 1.35 | 0.27 |
| Interest | 0.06 | 0.04 | 0.07 | 0.02 | 0.03 | 0.05 | 0.08 | 0.07 | 0.07 | 0.08 | 0.14 | 0.07 | 0.04 |
| Depreciation | 0.57 | 0.58 | 0.66 | 0.77 | 0.75 | 0.88 | 0.98 | 0.92 | 1.15 | 1.44 | 1.56 | 1.23 | 2.03 |
| Profit before tax | 23.57 | 25.18 | 13.19 | 15.53 | 23.81 | 16.89 | 17.69 | 20.95 | 17.86 | 14.19 | 17.40 | 16.09 | 12.12 |
| Tax % | 24.61% | 25.73% | 25.63% | 24.73% | 25.58% | 25.70% | 26.46% | 24.20% | 25.87% | 25.58% | 25.46% | 25.42% | 25.25% |
| Net Profit | 17.77 | 18.70 | 9.81 | 11.69 | 17.72 | 12.54 | 13.01 | 15.89 | 13.24 | 10.57 | 12.97 | 12.00 | 9.06 |
| EPS in Rs | 1.63 | 1.72 | 0.90 | 1.07 | 1.63 | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.10 | 0.83 |
Last Updated: August 21, 2025, 9:17 am
Below is a detailed analysis of the quarterly data for Gujarat Themis Biosyn Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 35.87 Cr.. The value appears to be declining and may need further review. It has decreased from 37.74 Cr. (Mar 2025) to 35.87 Cr., marking a decrease of 1.87 Cr..
- For Expenses, as of Jun 2025, the value is 21.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.70 Cr. (Mar 2025) to 21.95 Cr., marking an increase of 0.25 Cr..
- For Operating Profit, as of Jun 2025, the value is 13.92 Cr.. The value appears to be declining and may need further review. It has decreased from 16.04 Cr. (Mar 2025) to 13.92 Cr., marking a decrease of 2.12 Cr..
- For OPM %, as of Jun 2025, the value is 38.81%. The value appears to be declining and may need further review. It has decreased from 42.50% (Mar 2025) to 38.81%, marking a decrease of 3.69%.
- For Other Income, as of Jun 2025, the value is 0.27 Cr.. The value appears to be declining and may need further review. It has decreased from 1.35 Cr. (Mar 2025) to 0.27 Cr., marking a decrease of 1.08 Cr..
- For Interest, as of Jun 2025, the value is 0.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 2.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.23 Cr. (Mar 2025) to 2.03 Cr., marking an increase of 0.80 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.12 Cr.. The value appears to be declining and may need further review. It has decreased from 16.09 Cr. (Mar 2025) to 12.12 Cr., marking a decrease of 3.97 Cr..
- For Tax %, as of Jun 2025, the value is 25.25%. The value appears to be improving (decreasing) as expected. It has decreased from 25.42% (Mar 2025) to 25.25%, marking a decrease of 0.17%.
- For Net Profit, as of Jun 2025, the value is 9.06 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 9.06 Cr., marking a decrease of 2.94 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.83. The value appears to be declining and may need further review. It has decreased from 1.10 (Mar 2025) to 0.83, marking a decrease of 0.27.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 12:59 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30 | 31 | 33 | 36 | 39 | 41 | 85 | 91 | 115 | 148 | 170 | 151 | 148 |
| Expenses | 24 | 25 | 27 | 30 | 33 | 34 | 53 | 50 | 57 | 75 | 91 | 81 | 84 |
| Operating Profit | 6 | 7 | 6 | 6 | 6 | 7 | 32 | 40 | 58 | 74 | 79 | 70 | 64 |
| OPM % | 21% | 21% | 19% | 17% | 16% | 18% | 37% | 45% | 51% | 50% | 46% | 46% | 43% |
| Other Income | 0 | -0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 7 | 4 | 2 | 2 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 5 | 6 |
| Profit before tax | 5 | 5 | 5 | 5 | 5 | 8 | 31 | 41 | 59 | 77 | 79 | 66 | 60 |
| Tax % | 0% | 0% | 0% | 10% | 20% | 22% | 24% | 26% | 26% | 25% | 25% | 26% | |
| Net Profit | 5 | 5 | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 58 | 59 | 49 | 45 |
| EPS in Rs | 0.42 | 0.42 | 0.42 | 0.40 | 0.36 | 0.59 | 2.17 | 2.77 | 4.00 | 5.32 | 5.43 | 4.48 | 4.09 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 10% | 0% | 37% | 14% | 12% | 15% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | -20.00% | 0.00% | 50.00% | 300.00% | 25.00% | 46.67% | 31.82% | 1.72% | -16.95% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | -20.00% | 20.00% | 50.00% | 250.00% | -275.00% | 21.67% | -14.85% | -30.09% | -18.67% |
Gujarat Themis Biosyn Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: August 21, 2025, 9:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 11 |
| Reserves | -13 | -8 | -3 | 1 | 5 | 11 | 35 | 63 | 96 | 142 | 194 | 237 |
| Borrowings | 9 | 6 | 3 | 4 | 1 | 6 | 8 | 5 | 1 | 0 | 3 | 30 |
| Other Liabilities | 13 | 9 | 8 | 9 | 8 | 8 | 14 | 14 | 18 | 17 | 17 | 22 |
| Total Liabilities | 16 | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 |
| Fixed Assets | 11 | 10 | 9 | 11 | 11 | 15 | 17 | 19 | 19 | 33 | 38 | 41 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 13 | 21 | 91 | 184 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 5 | 5 | 5 | 11 | 10 | 17 | 47 | 67 | 90 | 113 | 92 | 76 |
| Total Assets | 16 | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 |
Below is a detailed analysis of the balance sheet data for Gujarat Themis Biosyn Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 4.00 Cr..
- For Reserves, as of Mar 2025, the value is 237.00 Cr.. The value appears strong and on an upward trend. It has increased from 194.00 Cr. (Mar 2024) to 237.00 Cr., marking an increase of 43.00 Cr..
- For Borrowings, as of Mar 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3.00 Cr. (Mar 2024) to 30.00 Cr., marking an increase of 27.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 5.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 301.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 221.00 Cr. (Mar 2024) to 301.00 Cr., marking an increase of 80.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 38.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Mar 2025, the value is 184.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Mar 2024) to 184.00 Cr., marking an increase of 93.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 76.00 Cr.. The value appears to be declining and may need further review. It has decreased from 92.00 Cr. (Mar 2024) to 76.00 Cr., marking a decrease of 16.00 Cr..
- For Total Assets, as of Mar 2025, the value is 301.00 Cr.. The value appears strong and on an upward trend. It has increased from 221.00 Cr. (Mar 2024) to 301.00 Cr., marking an increase of 80.00 Cr..
Notably, the Reserves (237.00 Cr.) exceed the Borrowings (30.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -3.00 | 1.00 | 3.00 | 2.00 | 5.00 | 1.00 | 24.00 | 35.00 | 57.00 | 74.00 | 76.00 | 40.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 15 | 28 | 24 | 71 | 26 | 52 | 87 | 59 | 80 | 44 | 58 | 76 |
| Inventory Days | 78 | 194 | 144 | 255 | 201 | 33 | 75 | |||||
| Days Payable | 947 | 240 | 84 | 145 | 131 | 99 | 218 | |||||
| Cash Conversion Cycle | 15 | 28 | 24 | 71 | -844 | 52 | 41 | 119 | 189 | 114 | -7 | -67 |
| Working Capital Days | -152 | -76 | -70 | -42 | -43 | -58 | 42 | 80 | 155 | 91 | 50 | 46 |
| ROCE % | 208% | 121% | 81% | 55% | 42% | 45% | 84% | 67% | 67% | 61% | 45% | 27% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Value Fund | 258,000 | 0.57 | 10.1 | N/A | N/A | N/A |
| Motilal Oswal BSE Healthcare ETF | 738 | 0.09 | 0.03 | 724 | 2025-08-21 01:55:48 | 1.93% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 4.48 | 8.14 | 39.90 | 30.03 | 20.77 |
| Diluted EPS (Rs.) | 4.48 | 8.14 | 39.90 | 30.03 | 20.77 |
| Cash EPS (Rs.) | 4.97 | 8.63 | 41.67 | 31.56 | 21.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 22.79 | 27.72 | 102.66 | 71.11 | 48.14 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 22.79 | 27.72 | 102.66 | 71.11 | 48.14 |
| Dividend / Share (Rs.) | 0.67 | 1.00 | 5.40 | 11.00 | 1.65 |
| Revenue From Operations / Share (Rs.) | 13.84 | 23.38 | 102.54 | 79.05 | 62.33 |
| PBDIT / Share (Rs.) | 6.54 | 11.44 | 55.23 | 42.74 | 29.42 |
| PBIT / Share (Rs.) | 6.05 | 10.95 | 53.46 | 41.20 | 28.23 |
| PBT / Share (Rs.) | 6.01 | 10.92 | 53.32 | 40.63 | 28.14 |
| Net Profit / Share (Rs.) | 4.48 | 8.14 | 39.90 | 30.03 | 20.77 |
| PBDIT Margin (%) | 47.26 | 48.93 | 53.86 | 54.06 | 47.19 |
| PBIT Margin (%) | 43.70 | 46.85 | 52.13 | 52.12 | 45.28 |
| PBT Margin (%) | 43.46 | 46.71 | 51.99 | 51.39 | 45.14 |
| Net Profit Margin (%) | 32.34 | 34.83 | 38.91 | 37.98 | 33.32 |
| Return on Networth / Equity (%) | 19.63 | 29.37 | 38.86 | 42.22 | 43.14 |
| Return on Capital Employeed (%) | 23.47 | 38.82 | 51.41 | 56.82 | 56.61 |
| Return On Assets (%) | 16.18 | 26.75 | 34.85 | 35.61 | 34.19 |
| Long Term Debt / Equity (X) | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.57 | 0.87 | 1.03 | 1.09 | 1.19 |
| Current Ratio (X) | 2.53 | 2.94 | 3.98 | 4.57 | 4.00 |
| Quick Ratio (X) | 2.28 | 2.74 | 3.03 | 3.89 | 3.62 |
| Inventory Turnover Ratio (X) | 36.02 | 2.86 | 2.27 | 2.46 | 2.61 |
| Dividend Payout Ratio (NP) (%) | 3.72 | 11.66 | 21.05 | 23.31 | 7.94 |
| Dividend Payout Ratio (CP) (%) | 3.35 | 11.00 | 20.15 | 22.17 | 7.51 |
| Earning Retention Ratio (%) | 96.28 | 88.34 | 78.95 | 76.69 | 92.06 |
| Cash Earning Retention Ratio (%) | 96.65 | 89.00 | 79.85 | 77.83 | 92.49 |
| Interest Coverage Ratio (X) | 195.82 | 362.56 | 399.81 | 75.01 | 329.82 |
| Interest Coverage Ratio (Post Tax) (X) | 134.99 | 259.13 | 289.83 | 53.70 | 233.87 |
| Enterprise Value (Cr.) | 3084.71 | 2869.27 | 987.92 | 579.63 | 268.24 |
| EV / Net Operating Revenue (X) | 20.46 | 16.90 | 6.63 | 5.05 | 2.96 |
| EV / EBITDA (X) | 43.28 | 34.53 | 12.31 | 9.33 | 6.28 |
| MarketCap / Net Operating Revenue (X) | 20.34 | 16.94 | 6.69 | 5.15 | 3.27 |
| Retention Ratios (%) | 96.27 | 88.33 | 78.94 | 76.68 | 92.05 |
| Price / BV (X) | 12.35 | 14.29 | 6.69 | 5.73 | 4.23 |
| Price / Net Operating Revenue (X) | 20.34 | 16.94 | 6.69 | 5.15 | 3.27 |
| EarningsYield | 0.01 | 0.02 | 0.05 | 0.07 | 0.10 |
After reviewing the key financial ratios for Gujarat Themis Biosyn Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.48. This value is below the healthy minimum of 5. It has decreased from 8.14 (Mar 24) to 4.48, marking a decrease of 3.66.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.48. This value is below the healthy minimum of 5. It has decreased from 8.14 (Mar 24) to 4.48, marking a decrease of 3.66.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.97. This value is within the healthy range. It has decreased from 8.63 (Mar 24) to 4.97, marking a decrease of 3.66.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.79. It has decreased from 27.72 (Mar 24) to 22.79, marking a decrease of 4.93.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.79. It has decreased from 27.72 (Mar 24) to 22.79, marking a decrease of 4.93.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has decreased from 1.00 (Mar 24) to 0.67, marking a decrease of 0.33.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 13.84. It has decreased from 23.38 (Mar 24) to 13.84, marking a decrease of 9.54.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 6.54. This value is within the healthy range. It has decreased from 11.44 (Mar 24) to 6.54, marking a decrease of 4.90.
- For PBIT / Share (Rs.), as of Mar 25, the value is 6.05. This value is within the healthy range. It has decreased from 10.95 (Mar 24) to 6.05, marking a decrease of 4.90.
- For PBT / Share (Rs.), as of Mar 25, the value is 6.01. This value is within the healthy range. It has decreased from 10.92 (Mar 24) to 6.01, marking a decrease of 4.91.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.48. This value is within the healthy range. It has decreased from 8.14 (Mar 24) to 4.48, marking a decrease of 3.66.
- For PBDIT Margin (%), as of Mar 25, the value is 47.26. This value is within the healthy range. It has decreased from 48.93 (Mar 24) to 47.26, marking a decrease of 1.67.
- For PBIT Margin (%), as of Mar 25, the value is 43.70. This value exceeds the healthy maximum of 20. It has decreased from 46.85 (Mar 24) to 43.70, marking a decrease of 3.15.
- For PBT Margin (%), as of Mar 25, the value is 43.46. This value is within the healthy range. It has decreased from 46.71 (Mar 24) to 43.46, marking a decrease of 3.25.
- For Net Profit Margin (%), as of Mar 25, the value is 32.34. This value exceeds the healthy maximum of 10. It has decreased from 34.83 (Mar 24) to 32.34, marking a decrease of 2.49.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.63. This value is within the healthy range. It has decreased from 29.37 (Mar 24) to 19.63, marking a decrease of 9.74.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.47. This value is within the healthy range. It has decreased from 38.82 (Mar 24) to 23.47, marking a decrease of 15.35.
- For Return On Assets (%), as of Mar 25, the value is 16.18. This value is within the healthy range. It has decreased from 26.75 (Mar 24) to 16.18, marking a decrease of 10.57.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.11, marking an increase of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.12. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.12, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has decreased from 0.87 (Mar 24) to 0.57, marking a decrease of 0.30.
- For Current Ratio (X), as of Mar 25, the value is 2.53. This value is within the healthy range. It has decreased from 2.94 (Mar 24) to 2.53, marking a decrease of 0.41.
- For Quick Ratio (X), as of Mar 25, the value is 2.28. This value exceeds the healthy maximum of 2. It has decreased from 2.74 (Mar 24) to 2.28, marking a decrease of 0.46.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 36.02. This value exceeds the healthy maximum of 8. It has increased from 2.86 (Mar 24) to 36.02, marking an increase of 33.16.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 3.72. This value is below the healthy minimum of 20. It has decreased from 11.66 (Mar 24) to 3.72, marking a decrease of 7.94.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.35. This value is below the healthy minimum of 20. It has decreased from 11.00 (Mar 24) to 3.35, marking a decrease of 7.65.
- For Earning Retention Ratio (%), as of Mar 25, the value is 96.28. This value exceeds the healthy maximum of 70. It has increased from 88.34 (Mar 24) to 96.28, marking an increase of 7.94.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.65. This value exceeds the healthy maximum of 70. It has increased from 89.00 (Mar 24) to 96.65, marking an increase of 7.65.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 195.82. This value is within the healthy range. It has decreased from 362.56 (Mar 24) to 195.82, marking a decrease of 166.74.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 134.99. This value is within the healthy range. It has decreased from 259.13 (Mar 24) to 134.99, marking a decrease of 124.14.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,084.71. It has increased from 2,869.27 (Mar 24) to 3,084.71, marking an increase of 215.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 20.46. This value exceeds the healthy maximum of 3. It has increased from 16.90 (Mar 24) to 20.46, marking an increase of 3.56.
- For EV / EBITDA (X), as of Mar 25, the value is 43.28. This value exceeds the healthy maximum of 15. It has increased from 34.53 (Mar 24) to 43.28, marking an increase of 8.75.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 20.34. This value exceeds the healthy maximum of 3. It has increased from 16.94 (Mar 24) to 20.34, marking an increase of 3.40.
- For Retention Ratios (%), as of Mar 25, the value is 96.27. This value exceeds the healthy maximum of 70. It has increased from 88.33 (Mar 24) to 96.27, marking an increase of 7.94.
- For Price / BV (X), as of Mar 25, the value is 12.35. This value exceeds the healthy maximum of 3. It has decreased from 14.29 (Mar 24) to 12.35, marking a decrease of 1.94.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 20.34. This value exceeds the healthy maximum of 3. It has increased from 16.94 (Mar 24) to 20.34, marking an increase of 3.40.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Themis Biosyn Ltd:
- Net Profit Margin: 32.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.47% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.63% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 134.99
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.28
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 112 (Industry average Stock P/E: 50.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.12
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 32.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot NO. 69-C, G.I.D.C., Valsad District Gujarat 396195 | cfoassist@themismedicare.com http://www.gtbl.in |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Dinesh S Patel | Non Executive Chairman |
| Dr. Sachin D Patel | Managing Director |
| Mr. Hitesh D Gajaria | Independent Director |
| Mr. K G Ananthakrishnan | Independent Director |
| Mr. Nihar Parikh | Independent Director |
| Mr. Siddharth Y Kusumgar | Independent Director |
| Mrs. Kirandeep Kaur Madan | Independent Director |
FAQ
What is the intrinsic value of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd's intrinsic value (as of 23 October 2025) is 443.97 which is 3.06% lower the current market price of 458.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,993 Cr. market cap, FY2025-2026 high/low of 465/192, reserves of ₹237 Cr, and liabilities of 301 Cr.
What is the Market Cap of Gujarat Themis Biosyn Ltd?
The Market Cap of Gujarat Themis Biosyn Ltd is 4,993 Cr..
What is the current Stock Price of Gujarat Themis Biosyn Ltd as on 23 October 2025?
The current stock price of Gujarat Themis Biosyn Ltd as on 23 October 2025 is 458.
What is the High / Low of Gujarat Themis Biosyn Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gujarat Themis Biosyn Ltd stocks is 465/192.
What is the Stock P/E of Gujarat Themis Biosyn Ltd?
The Stock P/E of Gujarat Themis Biosyn Ltd is 112.
What is the Book Value of Gujarat Themis Biosyn Ltd?
The Book Value of Gujarat Themis Biosyn Ltd is 22.8.
What is the Dividend Yield of Gujarat Themis Biosyn Ltd?
The Dividend Yield of Gujarat Themis Biosyn Ltd is 0.15 %.
What is the ROCE of Gujarat Themis Biosyn Ltd?
The ROCE of Gujarat Themis Biosyn Ltd is 27.3 %.
What is the ROE of Gujarat Themis Biosyn Ltd?
The ROE of Gujarat Themis Biosyn Ltd is 21.7 %.
What is the Face Value of Gujarat Themis Biosyn Ltd?
The Face Value of Gujarat Themis Biosyn Ltd is 1.00.